Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and NeckJay S. Cooper, Karen K. Fu, Thomas F. Pajak et al.|New England Journal of Medicine|2004Cited by 3.2k
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean M. McBride, Nancy Y. Lee, Eric J. Sherman et al.|Journal of Clinical Oncology|2020Cited by 393
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu‐Pei Chen, Nofisat Ismaila, Melvin L.K. Chua et al.|Journal of Clinical Oncology|2021Cited by 393